目的 分析2019—2022年我國9個城市125家醫(yī)院肝素類藥物使用情況，分析其使用趨勢，為醫(yī)院肝素類藥物的科學(xué)管理和臨床合理用藥提供參考。方法 隨機(jī)抽取參與中國藥學(xué)會醫(yī)院處方分析課題組研究的涉及使用肝素類藥物的處方信息，并計算肝素類藥物的銷售金額、銷售數(shù)量、用藥頻度（DDDs）、限定日費(fèi)用（DDC）、銷售金額排序（B）與DDDs排序（A）的比值以及年平均增長率（AARG），對臨床應(yīng)用情況進(jìn)行分析。結(jié)果 共抽取使用肝素類藥物處方/醫(yī)囑數(shù)據(jù)3 758 309條，涉及9個城市125家醫(yī)院。使用肝素類藥物患者男性多于女性，比例為1.1左右。2019—2022年銷售金額排名第1位的為依諾肝素鈉，銷售數(shù)量排名第1位的為肝素鈉，DDDs排名第1位的為依諾肝素鈉，歷年來只有貝米肝素鈉DDC大于100元，其余肝素類藥物DDC均在10～40元。結(jié)論 依諾肝素鈉的B/A等于1，此藥物使用同步性較好。那屈肝素鈣B/A小于1，說明此藥物使用頻率低而價格偏高。相反肝素鈉B/A大于1，此藥物使用頻率高而價格偏低。

Objective To analyze the use of heparins in 125 hospitals in 9 cities in China from 2019 to 2022, analyze their usage trends, and provide reference for the scientific management and clinical rational use of heparins in hospitals. Methods Randomly select prescription information related to the use of heparins from the research group on prescription analysis of hospitals under the Chinese Pharmaceutical Association, and calculate the sales amount, sales quantity, DDDs, DDC, sales amount ranking (B) to DDDs ranking (A), and annual average growth rate (AARG) of heparins to analyze their clinical application. Results A total of 3 758 309 prescriptions/medical orders for the use of heparins were extracted, involving 125 hospitals in 9 cities. More men than women use heparins, with a proportion of about 1.1. Between 2019 and 2022, enoxaparin sodium ranked first in terms of sales amount, heparin sodium ranked first in terms of sales quantity, and enoxaparin sodium ranked first in terms of usage frequency. Over the years, only bemiheparin sodium has a DDC greater than 100 yuan, while other heparinshave a DDC between 10 and 40 yuan. Conclusion The B/A of enoxaparin sodium is equal to 1, indicating good synchronicity in drug use. The B/A ratio of nadroparin calcium is less than 1, indicating that the frequency of use of this drug is low and the price is on the high side. On the contrary, if heparin sodium B/A is greater than 1, the frequency of use of this drug is high and the price is low.

R972

吳階平醫(yī)學(xué)基金會臨床科研專項項目（320.6750.2020-11-26）；天津市衛(wèi)生健康委員會科研項目（TJWJ2023QN114）